
Santa Monica-based ImmunoVec develops gene therapy treatments for terminal immune system diseases.
Founded in Santa Monica, California, ImmunoVec is dedicated to developing gene therapy treatments aimed at curing terminal genetic diseases of the immune system. The company's core mission is to provide life-saving therapies for hematopoietic diseases, leveraging advanced genetic engineering techniques to address conditions that currently have limited treatment options. ImmunoVec's vision is to revolutionize the field of gene therapy and offer hope to patients with otherwise incurable immune system disorders.
Notable figures associated with ImmunoVec include leading scientists and researchers in the field of gene therapy. The company has attracted significant attention from investors interested in cutting-edge medical technologies. Key achievements include successful preclinical trials demonstrating the efficacy of their gene therapy solutions. ImmunoVec's impact lies in its potential to transform the treatment landscape for severe immune system diseases, offering new possibilities for patients and advancing the field of genetic medicine.

Inimmune
inimmune.com

ImmunoGenesis
immunogenesis.com

Immusoft
immusoft.com

Immunitas Therapeutics
immunitastx.com

ImmuneTarget

ImmunGene

ImmuneBridge
immunebridge.com

Jaguar Gene Therapy

Locanabio

Immune-Onc Therapeutics
immuneonc.com

Immunome

Cancervax
cancervax.com

Rampart Bioscience
rampartbio.com

Excision BioTherapeutics

Immpact Bio
immpact-bio.com
Companies similar to ImmunoVec include Inimmune, ImmunoGenesis, Immusoft and Immunitas Therapeutics.
ImmunoVec was founded in 2019.
ImmunoVec's headquarters is located in Santa Monica, CA, US.
ImmunoVec's most recent funding round was for $4.3M (USD) in March 2022.
As of Mar 1, 2022, ImmunoVec has raised a total of $4.3M (USD).
ImmunoVec has 6 employees as of Feb 5, 2024.